See more : EJE (Hong Kong) Holdings Limited (8101.HK) Income Statement Analysis – Financial Results
Complete financial analysis of OrganiGram Holdings Inc. (OGI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of OrganiGram Holdings Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Splendid Metal Products Limited (SMPL.NS) Income Statement Analysis – Financial Results
- Population Health Investment Co., Inc. (PHICW) Income Statement Analysis – Financial Results
- Surrozen, Inc. (SRZN) Income Statement Analysis – Financial Results
- Brookfield Infrastructure Partners L.P. (BIP-UN.TO) Income Statement Analysis – Financial Results
- Suvanza Pharma, LLC (SUVZ) Income Statement Analysis – Financial Results
OrganiGram Holdings Inc. (OGI)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.organigram.ca
About OrganiGram Holdings Inc.
Organigram Holdings Inc., through its subsidiaries, produces and sells cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including cannabis flowers, cannabis oils, and vaporizers for civilian patients and veterans; adult use recreational cannabis under the Edison Cannabis Co., Trail Blazer, SHRED, SHRED'ems, Big Bag O' Buds, and Monjour brands; and cannabis edibles products and concentrates. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as telephone channels. Organigram Holdings Inc. was founded in 2013 and is headquartered in Moncton, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 159.84M | 149.21M | 145.81M | 79.16M | 86.80M | 80.41M | 12.43M | 5.71M | 6.13M | 986.68K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 112.32M | 114.13M | 114.24M | 107.56M | 143.29M | 31.94M | 39.20M | 8.84M | 813.38K | 339.51K | 274.91K | 0.00 | 0.00 |
| Gross Profit | 47.52M | 35.07M | 31.57M | -28.40M | -56.49M | 48.47M | -26.78M | -3.13M | 5.31M | 647.17K | -274.91K | 0.00 | 0.00 |
| Gross Profit Ratio | 29.73% | 23.51% | 21.65% | -35.87% | -65.08% | 60.28% | -215.42% | -54.73% | 86.73% | 65.59% | 0.00% | 0.00% | 0.00% |
| Research & Development | 11.20M | 12.19M | 5.96M | 3.45M | 1.27M | 409.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 48.29M | 48.95M | 42.35M | 30.72M | 29.94M | 26.67M | 9.27M | 4.78M | 2.31M | 1.76M | 66.77K | 318.91K | 140.16K |
| Selling & Marketing | 19.85M | 17.86M | 16.86M | 15.81M | 16.53M | 14.63M | 6.30M | 2.85M | 1.76M | 720.97K | 181.44K | 0.00 | 0.00 |
| SG&A | 68.14M | 71.68M | 59.21M | 46.52M | 46.47M | 41.30M | 15.57M | 7.62M | 4.07M | 2.49M | 66.77K | 318.91K | 140.16K |
| Other Expenses | 3.85M | 0.00 | 5.15M | -5.53M | -6.37M | 664.00K | 509.00K | 416.36K | 0.00 | 0.00 | 0.00 | 56.33K | 0.00 |
| Operating Expenses | 83.20M | 271.48M | 70.32M | 44.44M | 41.37M | 42.37M | 16.08M | 8.04M | 4.07M | 2.49M | 66.77K | 375.25K | 140.16K |
| Cost & Expenses | 195.51M | 385.61M | 184.56M | 152.00M | 184.65M | 74.31M | -23.99M | 16.88M | 4.88M | 2.15M | 66.77K | 375.25K | 140.16K |
| Interest Income | 0.00 | 3.69M | 1.49M | 854.00K | 308.00K | 662.00K | 0.00 | 9.87K | 0.00 | 0.00 | 996.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 277.85K | 429.00K | 2.96M | 6.01M | 9.67M | 10.09M | 273.87K | 436.37K | 115.41K | 996.00 | 0.00 | -140.16K |
| Depreciation & Amortization | 12.08M | 23.42M | 24.91M | 31.03M | 17.96M | 8.90M | 3.53M | 1.56M | 785.59K | 414.80K | 173.53K | 0.00 | 0.00 |
| EBITDA | -23.59M | -25.37M | -15.21M | -42.92M | -122.66M | 12.70M | 41.40M | -9.62M | 2.03M | -746.65K | 106.76K | -375.25K | -140.16K |
| EBITDA Ratio | -14.76% | -17.00% | -10.43% | -54.22% | -93.42% | 17.09% | 321.38% | -168.30% | 33.15% | -75.42% | 0.00% | 0.00% | 0.00% |
| Operating Income | -35.67M | -48.79M | -38.75M | -91.82M | -145.51M | 5.49M | 36.42M | -11.17M | 1.25M | -1.16M | -66.77K | -375.25K | -140.16K |
| Operating Income Ratio | -22.32% | -32.70% | -26.58% | -115.99% | -167.65% | 6.82% | 292.99% | -195.44% | 20.33% | -117.46% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -9.77M | -184.21M | 24.38M | -38.88M | -46.98M | -11.36M | -8.64M | 211.32K | -398.97K | -117.90K | 1.38M | 0.00 | 0.00 |
| Income Before Tax | -45.44M | -233.00M | -14.37M | -130.70M | -146.63M | -5.88M | 27.78M | -10.89M | 846.66K | -1.28M | -239.31K | -375.25K | 0.00 |
| Income Before Tax Ratio | -28.43% | -156.16% | -9.86% | -165.11% | -168.94% | -7.31% | 223.49% | -190.59% | 13.82% | -129.41% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 3.52M | -88.00K | 1.84M | -10.47M | 3.63M | 5.65M | -550.94K | -37.41K | 2.49K | 171.54K | 0.00 | 140.16K |
| Net Income | -45.44M | -229.48M | -14.28M | -132.55M | -136.16M | -9.50M | 20.51M | -10.89M | 846.66K | -1.28M | -239.31K | -375.25K | -140.16K |
| Net Income Ratio | -28.43% | -153.80% | -9.80% | -167.43% | -156.87% | -11.82% | 165.04% | -190.59% | 13.82% | -129.41% | 0.00% | 0.00% | 0.00% |
| EPS | -0.44 | -2.82 | -0.18 | -2.07 | -3.15 | -0.27 | 0.68 | -0.45 | 0.06 | -0.10 | -0.12 | -0.18 | -0.08 |
| EPS Diluted | -0.42 | -2.82 | -0.18 | -2.07 | -3.15 | -0.27 | 0.65 | -0.45 | 0.06 | -0.10 | -0.12 | -0.18 | -0.08 |
| Weighted Avg Shares Out | 103.80M | 81.29M | 77.23M | 64.03M | 43.17M | 35.23M | 30.14M | 24.30M | 14.67M | 13.10M | 2.07M | 2.07M | 1.75M |
| Weighted Avg Shares Out (Dil) | 108.38M | 81.29M | 77.23M | 64.03M | 43.17M | 35.23M | 31.72M | 24.30M | 14.67M | 13.10M | 2.07M | 2.07M | 1.75M |
OrganiGram purchasing Motif Labs to become Canada's largest cannabis company by market share, as others retreat
OrganiGram to pay up to C$100 million ($70.7 million) for vape and prerolled cannabis specialist Motif.
Organigram Acquires Motif, Becoming Canada's Largest Cannabis Company by Market Share
TORONTO--(BUSINESS WIRE)--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, is pleased to announce the acquisition of 100% of the issued and outstanding shares of Motif Labs Ltd. (“Motif”), for upfront consideration...
Organigram Could Soar In 2026
Organigram's stock is undervalued, trading at a 22% discount to tangible book value, with strong growth projections and a solid financial outlook. The company has a high cash balance and no debt, bolstered by additional investment from British American Tobacco....
Organigram Launches FAST™ Nanoemulsion Gummies
TORONTO--(BUSINESS WIRE)--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, is thrilled to finally launch Edison Sonics gummies, Organigram's inaugural product powered by FAST™, the Company's groundbreaking nanoemulsion technology and a first-to-market...
Organigram: Why I Still Like It
Organigram's stock has surged 22% since my last analysis, outperforming the cannabis market, yet it remains a buy due to its promising chart and valuation. The fiscal Q3 report exceeded expectations with revenue up 25% and adjusted EBITDA turning positive,...
3 Marijuana Stocks To Watch In The Stock Market Today
Many legal cannabis operators are working to keep pushing the boundaries of the industry. Innovation is key for any growing sector and cannabis is no different. Right now is a pivotal time for the cannabis industry as things are continuously...
Organigram Closes Second Tranche of Previously Announced BAT Private Placement Investment
TORONTO--(BUSINESS WIRE)--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today that on August 30, 2024, the Company closed the second of three tranches (the “Second Tranche”) of the previously announced...
CPS HR Consulting Partners with GovInvest to Revolutionize Compensation Consulting with Advanced Technology
SACRAMENTO, Calif.--(BUSINESS WIRE)--CPS HR Consulting, a leader in public sector HR consulting, is thrilled to announce a strategic partnership with GovInvest, the pioneer of compensation analytics technology for government agencies. This collaboration aims to combine CPS HR's renowned compensation consulting...
Top Canadian Marijuana Stocks To Watch In 2024
When it comes to finding top marijuana stocks to buy which companies would you choose? Now when going through this process there are some things to consider. For the most part, investing in all things is based on the same...
Next Week's Top Marijuana Stocks: Recent Big Gainers to Watch
The cannabis industry is buzzing with recent developments that could significantly impact its future. In July 2024, the U.S. Senate reintroduced the SAFE Banking Act to provide cannabis businesses with greater access to banking services. This move has reignited optimism...
Source: https://incomestatements.info
Category: Stock Reports